FRONTIERS IN ENDOSCOPY, SERIES #35Endoscopic Ultrasound Guided Gastroenterostomy for the Treatment of Gastroduodenal Outlet Obstruction
Here we discuss EUS-guided gastroenterostomy (EUS-GE) as a novel, minimally invasive technique that can be used to palliate the symptoms of gastroduodenal outlet obstruction due to benign or malignant conditions. Due to the risk for serious adverse events, no current standardized technique and limited published data, this endoscopic technique should only be undertaken by experienced endosonographers. Early results show promise in the treatment of gastric outlet obstruction.
NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #162Protein Losing Enteropathy: Diagnosis and Management
Protein losing enteropathy (PLE) is an uncommon etiology of hypoproteinemia. It is caused by protein loss from compromised gastrointestinal (GI) mucosa as a result of GI mucosal diseases, GI tract infections, as well as from disruptions of venous and lymphatic outflow. The prevalence of PLE is poorly understood given the wide variety of causes of both hypoalbuminemia and PLE, and due to a lack of systematic screening. The evaluation of a potential PLE patient includes a careful assessment for alternative causes of hypoalbuminemia and a measurement of GI tract protein loss. This review provides the clinician with diagnostic criteria, as well as management and nutrition support options.
GASTROINTESTINAL MOTILITY AND FUNCTIONAL BOWEL DISORDERS, SERIES #22Understanding the Etiology and Spectrum of Idiopathic Gastroparesis
Gastroparesis is a debilitating disease of delayed gastric emptying (GE) which affects approximately 10 million people in the United States. Diabetes-related and post-surgical gastroparesis are well-known entities, but the majority of patients with gastroparesis have no identifiable etiologies and are labeled as idiopathic (IG). Although post-infectious causation has been implicated in IG, the pathophysiology of IG remains elusive. Vagal nerve impairment, changes in enteric neurons, and depletion of interstitial cells of Cajal have been demonstrated. The diagnosis of IG is based on clinical symptoms and an abnormal scintigraphic gastric emptying study. This article aims to review new discoveries in idiopathic gastroparesis and update entities that may be incorrectly labeled idiopathic gastroparesis.
DISPATCHES FROM THE GUILD CONFERENCE, SERIES #3Detecting and Managing Dysplasia in Inflammatory Bowel Disease: 5 Key Tips
The field of IBD-related CRC prevention is evolving. Fortunately, important advances in disease management to control inflammation (primary prevention) as well as improved detection of precancerous lesions (secondary prevention) have transformed how we think about colorectal cancer and how we detect and manage dysplasia today even compared to 10 years ago. The following review discusses 5 key tips for detecting and managing dysplasia in patients with IBD today.
A CASE REPORTDuodenal Post-Transplant Lymphoproliferative Disorder (PTLD) with History of Heart Transplant
Pediatric short bowel syndrome (SBS) is associated with intestinal failure, prolonged parental nutrition (PN) use, impaired quality of life, and increased morbidity and mortality. Teduglutide is a glucagon-like peptide that may prevent some of the clinical complications of SBS by subsequent hormonal effects including increased epithelial proliferation of crypts and prolonged intestinal motility time to improve intestinal absorption and adaption.
Teduglutide and Pediatric Short Bowel Syndrome
Pediatric Crohns disease (CD) can be associated with intestinal complications including stricturing and penetrating disease, and the authors of this study evaluated potential risk factors for such complications in children by using data from the multi-center Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children with Crohn's Disease (RISK) study.
Disease Prediction Modeling in Pediatric Crohn's Disease
OSAKA, Japan & FLORHAM PARK, N.J. & STAMFORD, CN Shionogi Inc. and Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration (FDA) approved Symproic® (naldemedine) 0.2 mg tablets C-II as a once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.
FDA APPROVES SYMPROIC® (NALDEMEDINE) ONCE-DAILY TABLETS C-II FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION IN ADULTS WITH CHRONIC NON-CANCER PAIN
CENTER VALLEY, PA - Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced that it has received FDA 510(k) clearance of claims that the ENDOCUFF® endoscopic device, the previous iteration of its recently launched ENDOCUFF VISION, improves Adenoma Detection Rates (ADR) during colonoscopy over standard colonoscopy.
OLYMPUS ENDOCUFF NOW FDA 510(K)-CLEARED TO CLAIM IMPROVEMENT IN ADENOMA DETECTION RATE DURING COLONOSCOPY
NEW YORK - Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced that the company has submitted a supplemental New Drug Application (sNDA) for TRULANCE™ (plecanatide) for the treatment of adults with irritable bowel syndrome with constipation (IBS-C).
SYNERGY PHARMACEUTICALS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION(SNDA) FOR TRULANCE™ (PLECANATIDE) FOR THE TREATMENT OF ADULTS WITH IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C)